文献速递类风湿关节炎脊柱关节炎

炎症性关节炎患者COVID-19结局的前瞻性研究:共病与改善病情抗风湿药的影响

COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes.
PubMed 文献 · Arthritis Rheumatol · 2020-10-25

该前瞻性研究纳入103例炎症性关节炎(IA)合并症状性COVID-19患者,评估住院与死亡发生率,并分析共病及免疫调节药物与感染结局的关联。结果显示住院率26%、死亡率4%,住院者年龄更大且高血压和COPD更常见;口服糖皮质激素增加住院风险,而维持性抗细胞因子生物制剂不增加。

要点

  • IA合并COVID-19患者住院率26%,死亡率4%。
  • 住院者年龄更大,高血压和COPD更常见。
  • 口服糖皮质激素与住院风险增加相关,抗细胞因子生物制剂未显示风险增加。

核心结论

  • 在炎症性关节炎患者中,使用糖皮质激素者COVID-19结局更差,而维持性抗细胞因子治疗者结局未变差。

研究设计与样本

  • 前瞻性研究,通过基于网络问卷、电话随访和电子病历回顾收集103例炎症性关节炎(类风湿关节炎和脊柱关节炎)合并症状性COVID-19患者的数据。

主要发现

  • 103例患者中80例确诊COVID-19,23例高度疑似。
  • 住院率为26%,死亡率为4%。
  • 住院患者年龄更大(P < 0.001),合并高血压(P = 0.001)和慢性阻塞性肺疾病(P = 0.02)的比例更高。
  • 口服糖皮质激素与COVID-19住院可能性增加相关(P < 0.001),而维持性抗细胞因子生物制剂治疗未显示此关联。

临床怎么用

  • 对于炎症性关节炎患者,感染COVID-19时使用口服糖皮质激素可能增加住院风险,需谨慎评估。
  • 维持性抗细胞因子生物制剂治疗在COVID-19期间未显示增加住院风险。

局限性

  • 研究样本量较小(103例),且包含23例高度疑似病例而非全部确诊。
  • 需要进一步研究免疫调节治疗是否影响COVID-19发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the hospitalization and death rates among patients with inflammatory arthritis (IA) affected by coronavirus disease 2019 (COVID-19) and to analyze the associations of comorbidities and immunomodulatory medications with infection outcomes. METHODS: Data on clinical and demographic features, maintenance treatment, disease course, and outcomes in individuals with IA (rheumatoid arthritis and spondyloarthritis) with symptomatic COVID-19 infection were prospectively assessed via web-based questionnaire followed by individual phone calls and electronic medical record review. Baseline characteristics and medication use were summarized for hospitalized and ambulatory patients, and outcomes with the different medication classes were compared using multivariable logistic regression. RESULTS: A total of 103 patients with IA were included in the study (80 with confirmed COVID-19 and 23 with high suspicion of COVID-19). Hospitalization was required in 26% of the participants, and 4% died. Patients who were hospitalized were significantly more likely to be older (P < 0.001) and have comorbid hypertension (P = 0.001) and chronic obstructive pulmonary disease (P = 0.02). IA patients taking oral glucocorticoids had an increased likelihood of being admitted for COVID-19 (P < 0.001), while those receiving maintenance anticytokine biologic therapies did not. CONCLUSION: Among patients with underlying IA, COVID-19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Haberman RH, Castillo R, Chen A, et al. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol. 2020. PMID: 32725762. doi:10.1002/art.41456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。